JP2008503540A5 - - Google Patents

Download PDF

Info

Publication number
JP2008503540A5
JP2008503540A5 JP2007517234A JP2007517234A JP2008503540A5 JP 2008503540 A5 JP2008503540 A5 JP 2008503540A5 JP 2007517234 A JP2007517234 A JP 2007517234A JP 2007517234 A JP2007517234 A JP 2007517234A JP 2008503540 A5 JP2008503540 A5 JP 2008503540A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
rifamycin
matrix
colon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007517234A
Other languages
English (en)
Japanese (ja)
Other versions
JP5026262B2 (ja
JP2008503540A (ja
Filing date
Publication date
Priority claimed from IT001295A external-priority patent/ITMI20041295A1/it
Application filed filed Critical
Publication of JP2008503540A publication Critical patent/JP2008503540A/ja
Publication of JP2008503540A5 publication Critical patent/JP2008503540A5/ja
Application granted granted Critical
Publication of JP5026262B2 publication Critical patent/JP5026262B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007517234A 2004-06-25 2005-05-03 経口抗菌医薬組成物 Expired - Lifetime JP5026262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001295A ITMI20041295A1 (it) 2004-06-25 2004-06-25 Composizioni farmaceutiche antimicrobiche orali
ITMI2004A001295 2004-06-25
PCT/EP2005/052025 WO2006003043A1 (en) 2004-06-25 2005-05-03 Oral antimicrobial pharmceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008039159A Division JP2008163038A (ja) 2004-06-25 2008-02-20 経口抗菌医薬組成物

Publications (3)

Publication Number Publication Date
JP2008503540A JP2008503540A (ja) 2008-02-07
JP2008503540A5 true JP2008503540A5 (enExample) 2008-11-06
JP5026262B2 JP5026262B2 (ja) 2012-09-12

Family

ID=34968899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007517234A Expired - Lifetime JP5026262B2 (ja) 2004-06-25 2005-05-03 経口抗菌医薬組成物
JP2008039159A Withdrawn JP2008163038A (ja) 2004-06-25 2008-02-20 経口抗菌医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008039159A Withdrawn JP2008163038A (ja) 2004-06-25 2008-02-20 経口抗菌医薬組成物

Country Status (22)

Country Link
US (9) US8486446B2 (enExample)
EP (2) EP1894560A1 (enExample)
JP (2) JP5026262B2 (enExample)
KR (2) KR101157486B1 (enExample)
CN (2) CN1976685B (enExample)
AT (1) ATE392889T1 (enExample)
CA (2) CA2569683C (enExample)
CY (1) CY1108196T1 (enExample)
DE (1) DE602005006278T2 (enExample)
DK (1) DK1763339T3 (enExample)
ES (1) ES2303255T3 (enExample)
FI (1) FIC20190031I1 (enExample)
HR (1) HRP20080252T3 (enExample)
HU (1) HUS1900037I1 (enExample)
IT (1) ITMI20041295A1 (enExample)
MX (1) MXPA06014698A (enExample)
PL (1) PL1763339T3 (enExample)
PT (1) PT1763339E (enExample)
RS (1) RS50581B (enExample)
SI (1) SI1763339T1 (enExample)
WO (1) WO2006003043A1 (enExample)
ZA (1) ZA200610577B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
PL2011486T5 (pl) † 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
US8470885B2 (en) 2009-01-12 2013-06-25 Biokier, Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
MX2012003459A (es) 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
WO2012016707A2 (en) * 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form for the modified release of dimebolin
US20130259947A1 (en) * 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
EP4438039A3 (en) * 2017-11-10 2024-12-04 Cosmo Technologies Ltd. Oral rifamycin sv compositions
IT202000005782A1 (it) 2020-03-18 2021-09-18 Dpl Pharma S P A Formulazioni farmaceutiche a rilascio controllato per il trattamento di infezioni intestinali
KR102714380B1 (ko) * 2021-06-09 2024-10-11 강원대학교산학협력단 경구 투여용 나노입자 및 이의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE458505B (sv) * 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
CN1097306A (zh) * 1993-07-12 1995-01-18 中国医科大学第二临床学院 复方抗炎栓剂
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
SK180499A3 (en) * 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9910773D0 (en) 1999-05-11 1999-07-07 West Pharm Serv Drug Res Ltd Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
DK1183014T3 (da) * 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
CN1201736C (zh) * 2002-07-19 2005-05-18 安徽省药物研究所 甲硝唑结肠定位缓释制剂
NZ538998A (en) * 2002-08-26 2007-12-21 Sla Pharma Ag Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations

Similar Documents

Publication Publication Date Title
JP2008163038A5 (enExample)
AU2009266833B2 (en) Melt granulation process
JP2008503540A5 (enExample)
JP5918242B2 (ja) リファキシミンを含む医薬処方物、それを得るための方法及び腸疾患を治療する方法
JP2018507200A5 (enExample)
JP2017525712A5 (enExample)
RU2744576C2 (ru) Пероральные фармацевтические композиции месалазина
JP2011503048A5 (enExample)
CN104114163A (zh) 治疗心血管疾病的方法
CA2569683A1 (en) Oral antimicrobial pharmaceutical compositions
JP2022520170A (ja) アファビシン製剤、その作製方法及びその使用
ES2417330T3 (es) Minicomprimidos farmacéuticos para la liberación sostenida de acetato de flecainida
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2013169925A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
RU2018137323A (ru) Пероральные фармацевтические композиции никотинамида
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
WO2010023690A2 (en) Prolonged release formulation of amisulpride
JP2017502062A5 (enExample)
WO2012123922A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2017093444A1 (en) Compositions for oral administration in the treatment of inflammatory bowel disease
US20200054659A1 (en) Extended release capecitabine capsules
WO2016001843A1 (en) Extended-release gastroretentive tablets of voglibose
WO2020115774A1 (en) High drug load extended release formulations
WO2023067485A1 (en) Pharmaceutical combinations
WO2018142359A1 (en) Composition comprising immediate release and extended release capecitabine